Drug Discovery 2015

Presentation

Wed 2 September

3 September

DAY 1

Exhibition Area

Pattingham
Metabolic & Cardiovascular Drug Discovery

Beckbury
Chemistry Innovation in Lead Discovery

Wenlock
Target Identification & Validation

Ironbridge
Innovation in Assay Development & Screening

Jackfield

DAY 2

DAY 1

Exhibition Area

Pattingham
Metabolic & Cardiovascular Drug Discovery

Beckbury
Chemistry Innovation in Lead Discovery

Wenlock
Target Identification & Validation

Ironbridge
Innovation in Assay Development & Screening

Jackfield

DAY 2

8:00

Arrival, Registration & Coffee

8:00:

8:05:

8:10:

8:15:

8:20:

8:25:

8:30:

8:35:

8:40:

8:45:

8:50:

8:55:

9:00

9:00:

9:05:

9:10:

Session Chair Introduction
Chairs: Darren McKerrecher, AstraZeneca Paul Wyatt, University of Dundee

Session Chair Introduction
Chairs: Michael Schneider, Imperial College London Marcus Schindler, AstraZeneca R&D Mölndal

Session Chair Introduction
Chairs: Rachel Grimley, AstraZeneca Jon Moore, Horizon Discovery

Session Chair Introduction
Chairs: Steve Hill, University of Nottingham Anne Phelan, Pfizer Neusentis

9:10:

9:15:

Using Diversity-Oriented Synthesis to Enable Fragment-Based Lead Discovery
09:15 (45 mins)
Keynote Speaker: Damian Young, Baylor College of Medicine

Myocyte Lipotoxicity: A Chemical Biology Approach
09:15 (45 mins)
Keynote Speaker: Daniel P. Kelly, Sanford Burnham Prebys Medical Discovery Institute

Target Identification and Target Engagement: Applications in Drug Discovery
09:15 (45 mins)
Keynote Speaker: Friedrich Reinhard, Cellzome, a GSK company

Phenotypic Screening for Novel Druggable Targets Using "Protein-Interference"
09:15 (45 mins)
Keynote Speaker: Chris Torrance, PhoreMost Ltd

9:15:

9:20:

9:25:

9:30:

9:35:

9:40:

9:45:

9:50:

9:55:

10:00

Nanotechnology, Imaging and Targeted Drug Therapy in Cardiac Pathology
10:00 (30 mins)
Kim Kelly, University of Virginia

Design of Novel Building Blocks to Enhance Drug Discovery
10:00 (30 mins)
Frederick Goldberg, AstraZeneca

The Role of Systems Biology / Pharmacology in Choosing and Validating Targets
10:00 (30 mins)
Neil Benson, Xenologiq

The Kinetics of Drug-Receptor Binding: Why It Is Important and How We Can Measure It
10:00 (30 mins)
Steven Charlton, University of Nottingham

10:00

10:05

10:10

10:15

10:20

10:25

10:30

Coffee Break

10:30

10:35

10:40

10:45

10:50

10:55

11:00

Novel Inhibitors of MAP4K4 (HGK), an Acute Therapy to Prevent Cardiac Muscle Cell Death Following Myocardial Infarction
11:00 (30 mins)
Katie Chapman, Domainex

Phenotypic Drug Discovery: With A Lot of Help From Our Friends!
11:00 (30 mins)
Paul Wyatt, University of Dundee

Mass Spectrometry-Based Discovery Tools for Epigenetics
11:00 (30 mins)
Pete DiMaggio, Imperial College London

Biased Ligand Quantification in Drug Discovery: From Theory to High Throughput Screening to Identify New Biased µ Opioid Receptor Agonists
11:00 (30 mins)
David Winpenny, Pfizer Neusentis

11:00

11:05

11:10

11:15

11:20

11:25

11:30

Poster Tasters

11:30

11:35

11:40

11:45

11:50

11:55

12:00

Snapshot Presentations
Session: Metabolic & Cardiovascular Drug Discovery

Snapshot Presentations
Session: Chemistry Innovation in Lead Discovery

Snapshot Presentations
Session: Target Identification & Validation

Snapshot Presentations
Session: Innovation in Assay Development & Screening

12:00

12:05

12:10

12:15

12:20

12:25

12:30

Lunch - Exhibition - Posters - Workshops 1230hrs - 1350hrs

12:30

12:35

12:40

12:45

12:50

12:55

1:00

SLAS Author Workshop: How to Get Your Work Published
13:00 (60 mins)
Julio Martin Plaza, GlaxoSmithKline, Tres Cantos, Spain

1:00:

1:05:

1:10:

1:15:

1:20:

1:25:

1:30:

1:35:

1:40:

1:45:

1:50:

Welcome Words from the Chairman
Chairs: Sanj Kumar, ELRIG

1:50:

1:55:

2:00

Tackling Protein Trafficking Diseases
14:00 (60 mins)
David Thomas, Traffick Therapeutiques, Inc

2:00:

2:05:

2:10:

2:15:

2:20:

2:25:

2:30:

2:35:

2:40:

2:45:

2:50:

2:55:

3:00

Unravelling the Molecular Mechanisms of Proteinuria
15:00 (30 mins)
Tobias Huber, University of Freiburg

Structure-Kinetic Relationships: Investigating the Molecular Basis for Optimising Drug-Target Residence Time
15:00 (30 mins)
Mike Waring, AstraZeneca

The Impact of CRISPR/Cas9 on Target Identification and Validation
15:00 (30 mins)
Jon Moore, Horizon Discovery

Efficacy and Toxicity Assays Using iPS cells - Utilising Cells Reset to the Manufacturers Default Setting
15:00 (30 mins)
Julie Holder, Roslin Cells

3:00:

3:05:

3:10:

3:15:

3:20:

3:25:

3:30:

Synthetic Chemically modified mRNA (modRNA): Towards A New Technology Platform for Cardiovascular Biology and Medicine
15:30 (30 mins)
Ken Chien, Karolinska Instituet

All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery
15:30 (30 mins)
James Murray , Vernalis (R&D) Ltd

The Application of Synthetic Lethality to Cancer Treatment
15:30 (30 mins)
Chris Lord, Institute of Cancer Research

Functional Screening of Network Activity in Primary Neuronal Cultures Using a Novel Phenotypic Assay Platform
15:30 (30 mins)
Mattias Karlsson, Cellectricon AB

3:30:

3:35:

3:40:

3:45:

3:50:

3:55:

4:00

The Role of Post-Transcriptional Regulation in Cardiac Disease
16:00 (30 mins)
Norbert Hübner, Max-Delbrück-Center for Molecular Medicine (MDC)

Phage Selection of Bicyclic Peptides for Therapeutic Application
16:00 (30 mins)
Christian Heinis, Ecole Polytechnique Fédérale de Lausanne (EPFL)

New Targets for Virus-Induced Asthma Exacerbations: From Bedside to Bench
16:00 (30 mins)
Michael Edwards, Imperial College London

Nanobodies in Cell-Based Screening
16:00 (30 mins)
Miguel Conde, Ablynx

4:00:

4:05:

4:10:

4:15:

4:20:

4:25:

4:30:

Poster Session

4:30:

4:35:

4:40:

4:45:

4:50:

4:55:

5:00

Posters - Networking - Drinks Reception

5:00:

5:05:

5:10:

5:15:

5:20:

5:25:

5:30:

5:35:

5:40:

5:45:

5:50:

5:55:

6:00

6:00:

6:05:

6:10:

6:15:

6:20:

6:25:

6:30:

6:35:

6:40:

6:45:

6:50:

6:55:

7:00

7:00: